Loading
A phase 1/2 trial of AST-3424 in hepatocellular carcinoma, run by Ascentawits Pharmaceuticals, Ltd, active and no longer recruiting.
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239155 by Ascentawits Pharmaceuticals, Ltd, with 51 participants enrolled, started 2019-09-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: AST-3424.
Shares Ascentawits Pharmaceuticals and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.